摘要
目的为了了解重组人p53腺病毒注射液(商品名“今又生”)对大肠癌-174细胞株的体外抑制作用及其半数致死量(IC50),更好地指导临床应用。方法通过体外细胞培养、利用MTT法对比检测重组人p53腺病毒注射液与5-氟脲嘧啶、替加氟、顺铂、奥沙利铂、丝裂霉素以及紫杉醇等大肠癌常用化疗药物的IC50,明确重组人p53腺病毒注射液体外抑瘤活性的强弱;利用免疫组化检测技术检测重组人p53腺病毒体外转染大肠癌-174细胞株后,细胞凋亡、生长抑制与细胞内p53蛋白表达情况之间的关系。结果重组人p53腺病毒注射液具有良好的体外抑瘤效应,IC50为5.73×1011VP,且有剂量和时间依赖性;但其单用时的体外抑癌远远逊于经典的化疗药物如丝裂霉素、5-氟脲嘧啶和顺铂等;五种不同滴度的重组人p53腺病毒注射液在体外大肠癌-174细胞株转染过程中皆出现了阳性染色结果,最早的阳性染色结果出现在p53基因转染24小时后,而空白对照组的免疫组化染色皆为阴性。结论重组人p53腺病毒注射液具有明确的体外抑瘤效应,且有剂量和时间依赖性;但其单用时的体外-174细胞株的作用低于丝裂霉素、5-氧尿嘧啶和顺铂。
Objective To understand the inhibition and IC50 （50% inhibiting concentration） of the recombinant adenoviral p53 gene （rAd-p53） for the colorectal cancer ceils in vitro and to guide clinical practice. Methods We evaluate the efficiency （IC50） of the rAd-p53 and six kind of anti-cancer drugs （5-fluorouracil, tegafur, mitomycin c, cisplatin, oxaliplatin, paclitaxel） for human colorectal cancer cell line-174 through the cell culture and MTT chemosensitivity assay to make sure the anti-cancer capability of rAd- p53. Expression of p53 protein in transfection cells of colorectal cancer line-174 with rAd-p53 was evaluated by immunohistochemical stain. Results The rAd-p53 has good anti-cancer efficacy for the colorectal cancer cell line-174 in vitro, its IC50 is 5.73 × 10^11 VP （viral particles） and it is dose-dependent and timedependent. But its anti-cancer efficacy can＇t be compared with the classical chemical medicine mitomycin c, 5-fluorouracil and cisplatin et al when it used alone. The immunohistochemistry stain in blank control group is negative. However five different density of rAd-p53 are all appeared positive result in infected colorectal cancer cells with rAd-p53 and earliest positive result presented at 24 hours after infection. Conclusion The rAd-p53 has good anti-cancer efficacy for the colorectal cancer cell line-174 in vitro, it is dose and time-dependent manner. But its anti-cancer efficacy worse than those of the classical chemical medicine mitomycin c, 5-fluorouracil and cisplatin etc. when it was used alone.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2007年第3期185-188,232,共5页
Cancer Research on Prevention and Treatment
基金
陕西省自然科学研究基金资助项目(2003C250)
